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Abstract: The poor prognosis of head and neck squamous cell carcinoma (HNSCC) is partly due to the
lack of reliable predictive markers. Connexin 43 (Cx43) protein and its cell-communication channels
have been assigned tumor suppressor functions while the anti-apoptotic Bcl-2 (B-cell lymphoma-2)
protein has been associated with negative prognostic significance in cancer. This study aimed to
test the role of Cx43 protein on Bcl-2 expression, tumor progression and response to taxane-based
treatment in HNSCC. Human papillomavirus (HPV) negative HNSCC cell lines were tested for
paclitaxel sensitivity through measuring apoptosis induction, cell viability and changes in Cx43
and Bcl-2 levels using flow cytometry, cell viability assay, immunocytochemistry and western blot.
Inhibition of Cx43 expression using siRNA increased Bcl-2 protein levels in SCC25 (tongue squamous
cell carcinoma) cells, while forced Cx43 expression reduced Bcl-2 levels and supported paclitaxel
cytotoxicity in FaDu (hypopharynx squamous cell carcinoma) cells. In vitro results were in line with
protein expression and clinicopathological features tested in tissue microarray samples of HNSCC
patients. Our data demonstrate that elevated Cx43 and reduced Bcl-2 levels may indicate HNSCC
sensitivity to taxane-based treatments. On the contrary, silencing of the Cx43 gene GJA1 (gap junction
protein alpha-1) can result in increased Bcl-2 expression and reduced paclitaxel efficiency. Clinical
tumor-based analysis also confirmed the inverse correlation between Cx43 and Bcl-2 expression.
Keywords: head and neck cancer; paclitaxel; connexin 43; Bcl-2
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1. Introduction
An estimated 600,000 new head and neck cancers (tumors of the lip, oral cavity, larynx,
nasopharynx, oropharynx and hypopharynx) are diagnosed annually worldwide [1]. The 5-year
overall survival is only about 50%, which can be due to the fact that more than half of the tumors are
diagnosed at advanced stages [2].
Modern, targeted therapy drugs—such as the Food and Drug Administration (FDA) approved
cetuximab—shows clear benefit only for the treatment of recurrent or metastatic head and neck cancers
as first line therapy compared to chemotherapy [3]. Certain immune checkpoint inhibitors (anti-PD-1
(programmed cell death protein 1), anti-PD-L1 (programmed death-ligand 1) and anti-CTLA-4
(cytotoxic T-lymphocyte-associated antigen 4) antibodies) demonstrated clinical benefit and were
approved by FDA for patients with HNSCCs (head and neck squamous cell carcinoma) which showed
progression after treatment with platinum-based chemotherapy. However, there is a lack of reliable
predictive biomarkers for immunotherapy [4].
Currently, chemoradiotherapy (CRT) is still the most often used non-surgical therapeutic choice
in locoregionally advanced HNSCC. However, no biomarker is available to predict the therapeutic
response, resulting in a substantial number of patients who suffer the side effects of such a toxic treatment
without clinical benefit. Bioradiotherapy with cetuximab for the same setting has recently been shown
to be less effective than platinum-based CRT [5,6]. One of the therapeutic strategies for locally advanced
HNSCC is induction chemotherapy containing docetaxel/paclitaxel+platinum+5-fluorouracil (TPF) [7].
Trials demonstrated superiority of the TPF induction regimen over platinum+5-fluorouracil (PF) in the
management of locoregionally advanced HNSCC [8]. Paclitaxel is an antitumor agent that stabilizes
microtubules and blocks cells in G2/M phase [9].
One of the few potential predictive biomarkers is ERCC1 (excision repair cross-complementing
1) protein. Findings show that ERCC1 expression might predict response to chemotherapeutics like
5-fluorouracil/cisplatin in HNSCCs [10]. Another candidate biomarker is connexin 43 (Cx43) protein.
In vitro studies found a significant correlation between Cx43 expression and apoptosis inducing effect
of paclitaxel. Cell lines with high levels of Cx43 protein were the most sensitive to taxane-based
chemotherapy [11]. Paclitaxel therapy was also found to have the highest effect when high Cx43
expression was coupled with decreased expression of the specific antiapoptotic protein Bcl-2 (B-cell
lymphoma 2) [12].
Connexins, such as Cx43 are proteins acting as structural elements in the formation of gap
junctions. Gap junctions are responsible for intercellular communications allowing the transmission of
ions or small molecules between cells [13]. Besides, Cx43 is also a tumor suppressor. The decreased
expression of Cx43 correlates with tumor formation and poor prognosis in solid tumors such as breast
cancer and HNSCCs [14,15].
Bcl-2 family proteins are important regulators of apoptosis. This family of interacting partners
includes both inhibitors and inducers of cell death. Most Bcl-2 family proteins work on the membranes
of mitochondria and endoplasmic reticulum facilitated by their hydrophobic membrane anchoring
carboxyl-terminal domain. Bcl-2 protein increases the total cell number by preventing cell death rather
than by increasing cell division rate [16].
The aim of this study was to evaluate the predictive value of Cx43 and Bcl-2 expression and their
coexpression in HNSCCs when using paclitaxel chemotherapy.
2. Results
2.1. Expression of Cx43 and Bcl-2 in Head and Neck Cancer Cell Lines
Cx43 and Bcl-2 protein expression and localization were tested using western blot and
immunocytochemistry in HNSCC cell lines (Figure 1). According to western blot analysis, Detroit
562 (metastatic pharyngeal carcinoma) cells express Cx43 at a medium level compared to other two
cell lines. FaDu cells express approximately half (p = 0.05), whereas SCC25 (tongue squamous cell
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carcinoma) cells more than twice (p = 0.02) as much Cx43 than Detroit 562 cells. Expression of Cx43
is low in Detroit 562 and FaDu (hypopharynx squamous cell carcinoma), as opposed to SCC25 with
high protein expression. Regarding Bcl-2 protein, Detroit 562 cells show the highest expression level
with FaDu cells being close second (p = 0.22). In contrast, the SCC25 cells harbor very low amounts
of Bcl-2 protein, about one tenth of what Detroit 562 cells express (p = 0.05). Expression of Bcl-2 is
high in Detroit 562 and FaDu, as opposed to SCC25 with low protein expression. (Figure 1A,B) These
western blot results are in line with the data acquired by immunofluorescence imaging. Cx43 protein
was found to be localized in the nucleus, the cytoplasm and the plasma membrane of SCC25 cells.
Cx43 was also detected in the cytoplasm of Detroit 562 and FaDu cells. Bcl-2 protein was present in the
nucleus and the cytoplasm of all three cell lines (Figure 1C).
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against Cx43, Bcl-2 and the loading control, α-tubulin. (B) Densitometry analysis of Cx43 and Bcl-2 
protein expression in Detroit 562 (metastatic pharyngeal carcinoma), FaDu (hypopharynx squamous 
cell carcinoma) and SCC25 (tongue squamous cell carcinoma) cells. Quantitative PCR (qPCR) analysis 
of Cx43 and Bcl-2 mRNA expression in HNSCC cell lines. Densitometry analysis and qPCR analysis 
show the results of three independent experiments. The expressions of all proteins and mRNAs were 
normalized to the expression of α-tubulin. Data are presented as mean ± SD (standard deviation). 
Statistical analysis was performed by Student’s t-test, the Cx43 and Bcl-2 expression of the cell lines 
were compared to each other. *p < 0.05 (C) Representative immunofluorescence images of Cx43 and 
Bcl-2 expression in Detroit 562, FaDu and SCC25 cell lines. Cx43 and Bcl-2 were marked with Alexa 
Fluor 488 (green), nuclei were stained with DRAQ5 (blue). 
Figure 1. Expression of connexin 43 (Cx43) and B-cell ly phoma-2 (Bcl-2) in head and neck squamous
cell carcinoma (HNSCC) cell lines. (A) Cells were s j ted to western blot nalysis with antibodies
against Cx43, Bcl-2 and the loading control, α-tub l ( ) ensitometry nalysis of Cx43 and Bcl-2
protein expr ssion in Detroit 562 (metastatic phary l rcinoma), FaDu (hy opharynx squamous
cell carcinoma) and SCC25 (tongue squamous cell carcino a) cells. Quantitative PCR (qPCR) analysis
of Cx43 and Bcl-2 mRNA expression in HNSCC cell lines. Densitometry analysis and qPCR analysis
show the results of three independent experiments. The expressions of all proteins and mRNAs were
normalized to the expression of α-tubulin. Data are presented as mean ± SD (standard deviation).
Statistical analysis was performed by Student’s t-test, the Cx43 and Bcl-2 expression of the cell lines
were compared to each other. * p < 0.05 (C) Representative immunofluorescence images of Cx43 and
Bcl-2 expression in Detroit 562, FaDu and SCC25 cell lines. Cx43 and Bcl-2 were marked with Alexa
Fluor 488 (green), nuclei were stained with DRAQ5 (blue).
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As tested with quantitative real-time PCR (qPCR), Cx43 and Bcl-2 mRNA expression pattern
was in line with the protein levels measured with western blot. FaDu cells produced similar amount
(p = 0.40), whereas SCC25 cells expressed five times more Cx43 mRNA than Detroit 562 cells (p = 0.02).
Bcl-2 mRNA levels were not significantly different between FaDu and Detroit 562 cells (p = 0.26),
while SCC25 cells produced only negligible amount (p = 8e−04) of Bcl-2 compared to Detroit 562 cells
(Figure 1B). The published mRNA levels of these cell lines from Cancer Cell Line Encyclopedia are
consistent with our results [17].
2.2. Effect of Paclitaxel on the Viability of Head and Neck Cancer Cell Lines
Viability of HNSCC cells was analyzed in parallel experiments by using MTT after 72 h of
treatment with paclitaxel at different concentrations. Paclitaxel effectively decreased viability of all
three cell lines. However, SCC25 showed a significantly higher sensitivity to paclitaxel than the other
two cell lines (p = 0.002 and p = 5e−04). Detroit 562 and FaDu cell lines displayed moderate sensitivity
to paclitaxel. There is a slight, but statistically significant (p = 0.02) difference between the IC50 value
of Detroit 562 and FaDu cell lines (Figure 2).
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Figure 2. Effect of paclitaxel on cell viability. HNSCC cell lines were analyzed in parallel by MTT after
72 h of treatment with paclitaxel at different conce trations. (A) IC50 curves of paclitaxel o etroit 562,
FaDu and SCC25 cell lines. The r ults represent the mean of three ind pe nt experiments with SD.
(B) IC50 concentrations of pacl taxel measur d in Detro t 562, FaDu and SCC25 cell lines. IC50 values
are the mean of three different measurements ± SD. Statistical analysis was performed by Student’s
t-test, the IC50 concentrations of the cell lines were compared to each other. * p < 0.05.
2.3. Paclitaxel-Induced Apopt sis of Head and Neck Ca ll Lines
To reveal the mechanism of cell death caused by paclitaxel, we performed flow cytometry
experiments using Annexin V-FLUOS and PI (propidium iodide) double staining at one treatment time
(48 h) and five paclitaxel concentrations (1 nM, 3 nM, 10 nM, 33 nM, 100 nM). According to annexin
and PI positivity, four populations could be discerned: live cells, cells undergoing apoptosis, primary
necrotic and secondary necrotic cells. In Detroit 562 cell line, only a little increase of the apoptosis rate
could be observed. The proportion of cells undergoing apoptosis rose slightly with higher paclitaxel
concentrations compared to the control sample. This increase was not significant (p > 0.05). We could
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observe only a slight increase in the apoptosis rate in FaDu cell line. The proportion of cells undergoing
apoptosis rose with higher paclitaxel concentrations: there was a significant rise compared to control at
33 nM (p = 0.045) and 100 nM (p = 0.022) paclitaxel concentrations. In SCC25 cell line, a high increase
in apoptosis rate could be observed. The proportion of cells undergoing apoptosis rose with higher
paclitaxel concentrations. Significant differences could be seen between the control and the paclitaxel
treated samples even at 10 nM concentration (10 nM p = 0.033, 33 nM p = 0.025, 100 nM p = 0.027).
SCC25 showed a higher sensitivity to paclitaxel compared to the other two cell lines (Figure 3).
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Figure 3. Paclitaxel-induced apoptosis of Detroit 562, FaDu and SCC25 cells. Annexin V-FLUOS/
propidium iodide (Ann/PI)-stained HNSCC cells were analyzed by FACS (fluorescence-activated cell
sorting) after 48 h of treatment with paclitaxel different concentrations. Live cells are presented by the
Ann-/PI- fraction, apoptotic cells by the Ann+/PI- fraction, secondary necrotic cells by the Ann+/PI+
fraction and primary necrotic cells are detected in the Ann-/PI+ fraction. Data are presented as
mean ± SD. Statistical analysis was performed by Student’s t-test, the cell fractions at all concentrations
were compared to control fractions in each cell line * p < 0.05.
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2.4. Effects of GJA1 siRNA and Cx43 Plasmid Transfection on Protein Expression of Head and Neck Cancer
Cell Lines
In order to investigate whether Cx43 has any impact on the level of Bcl-2 protein, Cx43 gene (GJA1,
gap junction protein alpha-1) silencing and plasmid transfection were performed on HNSCC cell lines.
After GJA1 siRNA knockdown the Cx43 protein expression was significantly reduced in all three cell
lines (Detroit 562 p = 0.01, FaDu p = 3e−07, SCC25 p = e−11). This decrease had no effect on Bcl-2
expression in Detroit 562 (p = 0.22) and FaDu (p = 0.21) cells. However, knockdown of Cx43 in SCC25
resulted in a significant increase in Bcl-2 expression (p = 6e−04). The amount of Bcl-2 protein almost
doubled. (Figure 4A,C) Plasmid transfection upregulated Cx43 protein levels in all three cell lines,
but the difference was only significant in FaDu cells (p < 0.05) but not in Detroit 562 (p = 0.07), and
SCC25 (p = 0.22) cells. Forced Cx43 expression reduced Bcl-2 protein level in each cell line, which was
highly significant in FaDu (p = 8e−06) cells (Figure 4B,C) but not in Detroit 562 (p = 0.10) and SCC25
(p = 0.57) cells.
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Figure 4. Changes in the levels of Cx43 and Bcl-2 after GJA1 (gap junction protein alpha-1) siRNA
knockdown and Cx43 plasmid transfection in HNSCC cell lines. (A) Cx43 knockdown cells were
subjected to western blot analysis with antibodies against Cx43, Bcl-2 and the loading control, α-tubulin.
NT: non-targeting (B) Cx43 transfected cells were subjected to western blot analysis with antibodies
against Cx43, Bcl-2, GFP (green fluoresc nt pr t in) and the loa ing c ntrol, α-tubulin. GFP was
used to confirm transfect on success. ctrl: ontrol (C) Densitom try analysis of Cx43 and Bcl-2 protein
expression after GJA1 siRNA knockdown and Cx43 plasmid transfection in Detroit 562, FaDu and SCC25
cells. Densitometry analysis was performed using three independent experiments. The expressions
of all proteins were compared to those in the non-targeting siRNA treated negative controls or in the
control plasmid treated controls, after normalization to α-tubulin. Data are presented as mean ± SD.
Statistical analysis was performed using Student’s t-test, in each cell line the expression of all proteins
in GJA1 siRNA treated samples were compared to protein expression in non-targeting siRNA treated
samples or in Cx43 plasmid treated samples were compared to protein expression in control plasmid
treated samples. * p < 0.05.
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2.5. Effects of GJA1 siRNA on the Paclitaxel-Induced Apoptosis of SCC25 Cell Line
Since GJA1 siRNA had a significant effect on Bcl-2 protein expression in SCC25 cells, the possible
impact of this siRNA on paclitaxel-induced apoptosis was also investigated. In GJA1 siRNA treated
samples, the proportion of apoptotic cells in all paclitaxel concentrations decreased compared to the
negative control siRNA treated samples. This decrease was significant in 100 nM paclitaxel treated
samples (p = 0.02). The Cx43 protein expression was reduced in all GJA1 siRNA treated samples.
Knockdown of Cx43 resulted in an increase in Bcl-2 expression. Thus, GJA1 gene silencing explicitly
reduced the effect of paclitaxel in SCC25 cell line (Figure 5).Cancers 2019, 11, x FOR PEER REVIEW 8 of 20 
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Figure 5. Changes in the paclitaxel-induced apoptosis of SCC25 after knocking down Cx43. (A) Annexin
V-FLUOS/ propidium iodide (Ann/PI)-stained HNSCC cells were analyzed by FACS after 48 h of
treatment with pacli axel at differ nt concentrations. Live cells are presented by the Ann-/PI- fraction,
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necrotic cells are detected in the Ann-/PI+ fraction. Data are presented as mean ± SD. Statistical analysis
was performed by Student’s t-test, the cell fractions in all concentration were compared to negative
control fractions in non-targeting siRNA or GJA1 siRNA treated samples. The cell fractions in GJA1
siRNA treated samples were also compared to cell fractions in non-targeting siRNA treated samples. *
p < 0.05. (B) Cell lysates were subjected to western blot analysis with antibodies against Cx43, Bcl-2
and the loading control, α-tubulin. NT: non-targeting.
To strengthen our assumption, paclitaxel-induced apoptosis was also analyzed in FaDu and
Detroit 562 cell lines after applying GJA1 siRNA or non-targeting siRNA (Figures S1 and S2). We found
decreased paclitaxel sensitivity in the GJA1 siRNA treated FaDu cell line, which has low Cx43 but also
lower Bcl-2 expression than Detroit 562 cells. In case of Detroit 562, we did not observe remarkable
changes in paclitaxel sensitivity when we used GJA1 siRNA and non-targeting siRNA. The difference
between the sensitivity of the two cell lines with low Cx43 protein expression can be explained with
their different Bcl-2 protein expressions. Comparing with the other two cell lines, Detroit 562 cells had
low Cx43 protein expression, but the highest Bcl-2 protein level. The elevated level of Bcl-2 protein can
decrease the basal paclitaxel sensitivity of Detroit 562 cells. This could explain the lack of change in
paclitaxel sensitivity of Detroit 562 cells after silencing GJA1 gene.
Parallel with the analysis of cell apoptosis, cell proliferation was also examined in the same
samples of Detroit 562, FaDu and SCC25 cell lines with trypan blue exclusion test. The obtained results
confirmed our previous data, as the application of GJA1 siRNA decreased the effect of paclitaxel in both
SCC25 and FaDu cell lines (in particular in SCC25 cell line) but did not alter the paclitaxel sensitivity of
Detroit 562 cells (Figure S3, Table S1).
2.6. Effects of Cx43 Plasmid Transfection on the Paclitaxel-Induced Cell Death of FaDu Cell Line
Since forced Cx43 expression had a significant effect on Bcl-2 expression in FaDu cell line we
investigated how this can influence paclitaxel sensitivity. We analyzed the cell proliferation and
apoptosis using the same methods as for the GJA1 siRNA experiments. Although the flow cytometry
analysis showed a non-significant effect, the results of the trypan blue exclusion test revealed that the
Cx43 transfection can sensitizes FaDu cells to paclitaxel treatment. Cx43 plasmid transfected FaDu
cells had lower paclitaxel IC50 values (Figure 6).
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2.7. Cx43 and Bcl-2 Expression in Patient-Derived HNSCC Samples
High Cx43 expression (Cx43H) was found in 44/58 (75.9%) of HNSCCs. Cx43 status correlated
with disease-specific survival (DSS, p = 0.024), the reduction of Cx43 expression level was associated
with a better prognosis. The Cx43 status did not correlate with tumor localization (p = 0.779), tumor
size (p = 0.824), stage (p = 0.638), lymph node metastasis (p = 0.351) or response to neoadjuvant
chemotherapy (p > 0.05).
Of the 58 tumor samples 9 (15.5%) cases showed high Bcl-2 expression (Bcl-2H). The Bcl-2 status
did not correlate with DSS (p = 0.21), tumor localization (p = 0.531), tumor size (p = 0.136), stage
(p= 0.748), lymph node metastasis (p = 0.111) or response to neoadjuvant chemotherapy (p = 0.544).
However, the reduction in Bcl-2 expression was associated with poorer prognosis in oropharyngeal
samples, this phenomenon was not significant (p = 0.056). It has been observed that lymph node
metastasis occurs more frequently in Bcl-2H cases (of the 9 Bcl-2H tumor samples, 7 proved to bear
lymph node metastasis).
Correlation between Cx43 and Bcl-2 protein expression was also investigated. Low Cx43 expression
(Cx43L) / low Bcl-2 expression (Bcl-2L) cases were found to be 13.8% (8/58), Cx43H/Bcl-2L 70.7% (41/58),
Cx43L/Bcl-2H 10.3% (6/58), Cx43H/Bcl-2H 5.2% (3/58). Typical Cx43H/Bcl-2L (A) and Cx43L/Bcl-2H (B)
tissue samples are depicted in Figure 7. Low Cx43 expression was associated with high Bcl-2 expression
(p = 0.013). This finding implies that Cx43 negative tumors overexpress Bcl-2 more often than Cx43
positive ones. (Figure 8) The combined status of Cx43 and Bcl-2 did not correlate with DSS (p > 0.05),
tumor localization (p = 0.904), tumor size (p = 0.687), stage (p = 0.924), lymph node metastasis (p = 0.43)
or response to neoadjuvant chemotherapy (p > 0.05).
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expression as a potential redic ive molecular marker of tax n drug sensitivity was investigated in
HNSCC cell lines and tumor cells.
Bcl-2 family proteins are key regulators of apoptosis. Bcl-2 increases the total cell number by
preventing cell death rather than by increasing cell division rate [16]. HNSCCs of en overexpress the
anti-apoptotic Bcl-2 protein, which prov d to be assoc ated with chemoresistance [18]. Bcl-2 is also a
possible therapeutic target in combination with chemoth rapy [19].
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(FFPE) tumor samples. We found that the investigated cell lines and tissue samples have different
Cx43 and Bcl-2 expression. No significant association was found between Bcl-2 or Cx43 expression
and patients clinicopathological data, such as stage, grade, localization or disease specific survival.
However, interestingly, most of the patients with high Cx43 expression had worse outcome than those
with low Cx43 expression. Although due to the low number of patients, these data have to be managed
carefully, our result is consistent with the previous founding of Brockmeyer et al. [25].
Considering the relationship between Cx43 and Bcl-2 protein levels, it seems that high level of
Cx43 is usually associated with weak expression of Bcl-2. The best example of this phenomenon is
SCC25 cell line with the highest Cx43 and lowest Bcl-2 level which is the most sensitive to paclitaxel at
the lowest IC50 value and the highest fraction of apoptotic cells. At the same time, low level of Cx43 was
associated with increased Bcl-2 protein level and relatively lower paclitaxel sensitivity in the remaining
two cell lines. The observed phenomenon, that elevated basal Bcl-2 protein level can decrease paclitaxel
sensitivity despite higher Cx43 protein as seen in Detroit 562 cell line, can highlight the importance of
Bcl-2 protein besides Cx43. Our results are in line with previous findings in glioblastoma cell lines
where high expression level of Cx43 was accompanied by low Bcl-2 expression and high sensitivity
to therapies containing taxane agents [12]. Similar effects were observed in transfected ovarian [32]
and prostate cancer cell lines [33] in vitro and in mouse models. Huang et al. hypothesized that this
mechanism could be independent of the gap junctional intercellular communication of Cx43, because
in their cell model, Cx43 was localized mainly in the cytoplasm and the nucleus. They analyzed several
apoptosis related genes (Bcl-2, Bax-1, Bac-1, Mcl-1) and found significant changes only in the protein
level of Bcl-2 [34]. Zhang et al. observed that the enforced expression of Cx43 increased the protein
level of the CDK inhibitor p27 in the osteosarcoma U2OS cells, they found no significant changes in the
protein level of cyclin A, D1, E, CDK2, CDK4, CDK6, p15, p18 or p21 [35]. The exact mechanism by
which Cx43 regulates gene expression is complex and still remains to be elucidated. In the SCC25 cell
line, Cx43 is also localized in the nucleus, like the transfected Cx43 in the experiments of Huang et al.
They considered that Cx43 directly binds to cis elements in the promoter region and regulates gene
expression [12]. Another possible mechanism could affect through signal transduction, because Cx43
exhibits SH2 and SH3 binding sites, and inhibits the activity of c-Src. Wang et al. observed that the
upregulation of Cx43 expression only sensitized colorectal cancer cells to paclitaxel when they were
cultured at high density and cells were in contact with each other. This may indicate the importance of
Cx43 gap junctional function in the mechanism of chemosensitization [11]. Cx43 binds to tubulin and
is also involved in the stabilization of microtubules which can also have an impact on the effect of
paclitaxel. Nevertheless, in our research we did not aim to investigate the direct interaction between
Cx43 and microtubules [36].
In our study using tumor cell lines, we found an inverse association between Cx43 and Bcl-2
protein expression in the FFPE HNSCC tissue samples. High protein expression of Cx43 and low
expression of Bcl-2 occurred frequently together which phenomenon proved to be significant. No
significant correlation was verified between the effect of neoadjuvant TPF chemotherapy and the
protein level of Cx43 or Bcl-2 but the low number of cases have to be considered (only 18 patients
received TPF therapy). To verify the revealed inverse association between protein expression of Cx43
and Bcl-2 we used the mRNA expression data of head and neck tumors from TCGA (The Cancer
Genome Atlas Program.) The database GEPIA (Gene Expression Profiling Interactive Analysis) allows
us to perform pairwise gene correlation analysis of TCGA expression data. We analyzed the gene
expression of GJA1 and BCL-2 in HNSCCs and found a significant inverse correlation (p = 2.4e−06, R =
−0.21), which can confirm our result [37]. We could not isolate mRNA of appropriate quality from our
FFPE HNSCC tissue samples.
In the present work, we used RNA interference and plasmid transfection to demonstrate the effect
of Cx43 protein level on Bcl-2 expression. We found that significant reduction of Cx43 protein resulted
a significantly elevated Bcl-2 protein expression in SCC25 cell line, whereas in FaDu cell line significant
elevation of Cx43 protein resulted in a significantly decreased Bcl-2 protein expression. In case of
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RNA interference, we did not reveal any significant change in Bcl-2 protein level of FaDu and Detroit
562 which might be due to their low initial Cx43 protein expression and to the consequently small
change in Cx43 protein levels in response to RNA interference. Huang et al. [12] found similar effects
when transfecting Cx43 into glioblastoma cell lines. The decreased Cx43 expression in SCC25 cell lines
lead to a lower paclitaxel sensitivity, decreased fraction of apoptotic cells while the increased Cx43
expression lead to a higher paclitaxel sensitivity in FaDu cell line. GJA1 gene transfection resulted in
increased Cx43 protein expression in all three cell lines, but the difference was significant only in FaDu
cells. Their use for further experiments was also supported by their most efficient and best tolerance for
transfection. In transfected Detroit 562 cells, elevated Cx43 expression decreased or almost disappeared
after two days. The lack of significant change in Bcl-2 protein level in SCC25 cells might be due to
the high initial Cx43 protein levels and which showed only minor increase in response to plasmid
transfection. Though GJA1 transfection did not induce significant apoptosis, it could sensitize FaDu
cells to paclitaxel treatment transfection by itself cased some cell death, and since it was more efficient
with the smaller control plasmid compared to the construct this led to a non-significant difference in cell
death between these experiments. This disturbing effect did not change much when the transfection
agents were reduced.
In summary, these data suggest that the expression of Cx43 and Bcl-2 are inversely correlated in
head and neck cancer cell lines and tissue samples as well. High level of Cx43 and low level of Bcl-2
predicted a good response to paclitaxel treatment in the investigated cell lines. The specific role of
Cx43 in this phenomenon was proved by using RNA interference and GJA1 gene transfection.
4. Materials and Methods
4.1. Cell Culturing and Inhibitors
Head and neck squamous cell carcinoma cell lines Detroit 562 (CCL-138™), FaDu (HTB-43™) and
SCC25 (CRL-1628™) were obtained from American Type Culture Collection (ATCC). Detroit 562 cells
were cultured in EMEM (Lonza) supplemented with 10% (V/V) fetal bovine serum (FBS, GIBCO), 0.1%
(V/V) sodium pyruvate (Lonza) and 1% (V/V) antibiotic mix (MycoZap Plus-CL, Lonza). FaDu cells
were maintained DMEM (Lonza) supplemented with 10% (V/V) fetal bovine serum (FBS, GIBCO),
0.1% added sodium pyruvate (Lonza) and 1% antibiotic mix (MycoZap Plus-CL, Lonza). SCC25 cells
were cultured DMEM:F12 (Lonza) supplemented with 10% (V/V) fetal bovine serum (FBS, GIBCO),
400 ng/mL hydrocortisone (STEMCELL) and 1% antibiotic mix (MycoZap Plus-CL, Lonza) respectively
in humidified atmosphere at 37 ◦C and 5% CO2. Cells were checked for mycoplasma (MycoAlert™
PLUS Mycoplasma Detection Kit, Cat. No. LT07-705, Lonza, Basel, Switzerland). Paclitaxel (Cat. No.
S1150) was purchased from Selleckchem (Houston, TX, USA).
4.2. Cell Viability Assay
Cell viability assay was carried out as mentioned previously [38]. Briefly, HNSCC cells were
seeded into 96 well plates at a density of 4 × 103 cells/well.
Cell lines were left overnight to attach, then treated with decreasing concentrations of paclitaxel
in duplicates. Following this, 72 h after treatment, medium was removed and 50 µL PBS containing
1 mg/mL 3-(4,5-dimethylthiaziazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was added to
each well and cells were incubated for 1 h at 37 ◦C. After the incubation MTT solution was removed
and tetrazolium crystals were dissolved in isopropanol containing 10% (V/V) Triton X-100 and 1%
(V/V) 0.1 N HCl. Absorbance was measured at 570 nm and 690 nm with a Synergy multimode reader
(BioTek, Budapest, Hungary). The 690 nm data was subtracted from the 570 nm for each well. Absolute
IC50 values were calculated by non-linear regression using Graph Pad Prism 5 software (GraphPad
Software, San Diego, CA, USA). Each experiment was repeated at least three times.
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4.3. Trypan Blue Exclusion Test
The proliferation of GJA1 siRNA + paclitaxel and non-targeting siRNA + paclitaxel treated
Detroit 562, FaDu and SCC25 cells as well as Cx43 plasmid + paclitaxel and control plasmid +
paclitaxel treated FaDu cells was determined by the direct counting of cells after 0.4% Trypan Blue
solution (Sigma-Aldrich, St. Louis, MO, USA) staining in 1:1 ratio. Cell number was counted with
hemocytometer. Absolute IC50 values were calculated by non-linear regression using Graph Pad Prism
5 software. Each experiment was repeated at least three times.
4.4. Quantitative Real-Time PCR (qPCR)
Total RNA was purified from the cells by using RNeasy Plus Mini Kit (Qiagen, Hilden, Germany)
following the manufacturer’s instruction. cDNA was produced by reverse transcription of 1 µg DNA
free RNA samples using SuperScript III First-Strand Synthesis System for RT-PCR Kit (Thermo Fisher
Scientific, Waltham, MA, USA).
Quantitative real-time PCR assay was performed in 20 µL final volume containing 5 µL cDNA, 1×
Prime Time Gene Expression Master Mix (Cat. No. 1055770, IDT, Coralville, IA, USA), 1× Prime Time
qPCR assay (BCL2 (Cat. No. Hs.PT.56a.654557.g), GJA1 (Cat. No. Hs.PT.56a.38338544) and TUBA4A
(Cat. No. Hs.PT.58.4392157.g); IDT)) using QuantStudio 12K Flex Software v1.2.2. Denaturation at
95 ◦C, 3 min was followed by 40 cycles (95 ◦C, 5 s and 60 ◦C, 30 s). Reactions were performed in
triplicate using RNase-free water as negative control. CT-values were set in the exponential range of
the amplification plots using the QuantStudio Detection Software. Relative expression levels were
expressed as 2−∆∆CT where ∆∆CT values correspond to the difference between the CT-values of the
target and the TUBA4A internal control genes.
4.5. Western Blot Analysis
Cells were grown until 90% confluence in 6 well plates and incubated for 48 h in medium. After
incubation, cells were washed with ice-cold PBS and lysed in lysis buffer (50 mM Tris (pH 7.4), 150 mM
NaCl, 1% (V/V) NP-40, 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, phosphatase inhibitor cocktail
(Merck, Kenilworth, NJ, USA) and protease inhibitor cocktail (Calbiochem)) for 30 min on ice. Lysates
were centrifuged with 13,000× g at 4 ◦C for 15 min. Then, 10 µg protein samples were subjected to
SDS-PAGE and electrotransferred to polyvinylidene-difluoride (PVDF) membranes. Membranes were
incubated with the diluted primary antibodies at 4 ◦C overnight, and with horse radish peroxidase
(HRP) conjugated secondary antibodies for 1 h at room temperature. Bcl-2 (clone 124, Cat. No. 15071,
dilution 1:1000), Connexin 43 (Cat. No. 3512, dilution 1:1000), GFP (clone 4B10, Cat. No. 2955,
dilution 1:1000) monoclonal antibodies were purchased from Cell Signaling Technology (Danvers,
MA, USA) and α-tubulin (clone DM1A, Cat. No. T9026, dilution 1:40,000) monoclonal antibody was
purchased from Merck Millipore (Burlington, MA, USA). Anti-mouse IgG (Cat. No. 7076, dilution
1:8000), Anti-rabbit IgG (Cat. No. 7054, dilution 1:2000) secondary antibodies were purchased from
Cell Signaling Technology. Bands were visualized by Enhanced Chemiluminescence (ECL) detection
system (Perkin Elmer, Waltham, MA, USA) and quantified by ImageJ v1.48 software. Every experiment
was carried out at least three times. The original western blots found in the Supplementary Materials
(Figures S4–S10).
4.6. Immunofluorescence Imaging of Cells
Cells were seeded into Ibidi µ-Slide 8 Well microscopic slide at the density of 2 × 104 cells/well.
After incubation, cells were washed with PBS and fixed in 4% paraformaldehyde solution (Bio-Optica)
for 10 min. Then cells were washed with PBS and cell membrane was permeabilized with PBS
containing 0.1% (V/V) Triton-X 100 for 15 min. After permeabilization, cells were washed three times
with PBS for 5 min and blocking solution (PBS containing 10% (V/V) inactivated FBS) was added to
each well and the plate was incubated for 1 h at room temperature. Blocking solution was discarded
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and diluted Bcl-2 (124) or Connexin 43 primary antibody in PBS containing 10% (V/V) FBS was added
to the wells. Connexin 43 (Cat. No. 3512, dilution 1:100) monoclonal antibody was purchased from
Cell Signaling Technology. Bcl-2 Monoclonal Antibody (clone 100/D5, Cat. No. MA5-11757, dilution
1:100) was purchased from Thermo Fisher Scientific. Plate was incubated overnight at 4 ◦C. Next, the
primary antibody solution was discarded, and cells were washed three times with PBS for 5 min. Alexa
Fluor 488 conjugated anti-rabbit IgG (Cat. No. A11001, Jackson Immuno Research, Cambridgeshire,
United Kingdom) was diluted in PBS containing 10% (V/V) FBS (dilution 1:500), added to each well
and incubated for 1 h at room temperature in the dark. Cells were washed three times with PBS for
5 min and were incubated with 10 µM Draq5™ in PBS for 10 min at room temperature in the dark.
The wells were washed three times with PBS for 5 min and a few drops of mounting media (Cat. No.
F4680-25ML, Merck Millipore) were added. Cells were analyzed using confocal laser microscope (Zeiss
Confocal LSM 710, Carl Zeiss AG, Oberkochen, Germany) under 63× oil-immersion objective. Images
were created and exported by Zen lite 2.5 software.
4.7. Flow Cytometry Analysis
Thus, 3 × 104 of Detroit 562, FaDu and SCC25 cells were seeded into each well of a 24 well plate
and let to attach for 48 h. Then culture medium was changed to complete medium containing paclitaxel
at the indicated concentrations. After 48 h, supernatants were collected into polypropylene test tubes.
Cell cultures were washed with 150 µL PBS/well that was also pipetted into the respective test tube.
Then cells were trypsinized with 135 µL trypsin-EDTA (GIBCO, 15 min, 37 ◦C), suspended with 150 µL
complete medium and 500 µL PBS and pipetted into the respective test tubes.
For apoptosis detection, trypsinized cell suspensions were centrifuged (250× g, 4 min, room
temperature) and supernatants were removed. Pellets were washed once with 1 mL PBS, centrifuged
(250× g, 4 min, room temperature) and incubated with 100 µL Binding Buffer supplemented with 2 µL
Annexin V-FITC conjugate (20 min, room temperature, dark) as recommended by the manufacturer
(ROCHE, Ref.: 11828681001). After the incubation, 1 mL PBS was pipetted into each tube and cells
were centrifuged again as a washing step (250× g, 4 min, room temperature). Pellets were suspended in
300 µL PBS supplemented with 3 µL propidium iodide (10 ng/mL final concentration). Compensation
was adjusted and the proportion of fluorescent cell populations was detected with a FACSCalibur flow
cytometer using CellQuest Pro software (BD Biosciences, San Jose, CA, USA). Sample evaluation was
performed with CellQuest Pro and Excel (Microsoft) software. Treatment groups were replicated at
least three times.
4.8. RNA Interference
In total, 2 × 105 of Detroit 562, FaDu and SCC25 cells were seeded into each well of a 6 well plate
and let to attach for 48 h. Gap junction protein alpha 1 (GJA1) short interfering RNAs (ON-TARGETplus
Human GJA1 (2697) siRNA–SMARTpool, Cat. No. L-011042-00-0005) were purchased from Dharmacon
(Table 1). Ambion Non-targeting control #1 siRNA (Silencer®Select Negative Control #1 siRNA,
Cat. No. 4390843) was ordered from Thermo Fisher Scientific. Transfection was carried out using
Lipofectamine RNAiMAX (Cat. No. 13778075, Thermo Fisher Scientific) and OPTI-MEM media (Cat.
No. 31985070, GIBCO) at the indicated concentrations following the manufacturers’ protocols. After
24 h, medium was changed to cell culture medium. Cells were used for other experiments (trypan blue
exclusion test, western blot analysis and flow cytometry analysis) after additional 24 h of incubation.
Table 1. Gap junction protein alpha 1 (GJA1) short interfering RNA target sequences.
siRNA No. Target Sequence
J-011042-05 CAGUCUGCCUUUCGUUGUA
J-011042-06 UGACAAGGUUCAAGCCUAC
J-011042-07 GUACAUCUAUGGAUUCAGC
J-011042-08 GAACCUACAUCAUCAGUAU
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4.9. Overexpression of Cx43
Cx43 was overexpressed in HNSCC cell lines using a pIRES2-Cx43 vector coding for wild-type
Cx43 (wtCx43), kindly gifted by Professor David Laurence Becker (Lee Kong Chian School of Medicine,
Nanyang Technological University, Singapore) [39]. A GFP-producing plasmid was used as a control.
105 of Detroit 562, FaDu and SCC25 cells were seeded into each well of a 12 well plate and let to attach
for 48 h. Transfection into the HNSCC cells was performed using Lipofectamine®LTX & PLUS™
Reagent (Cat. No. 15338100, Thermo Fisher Scientific), according to the manufacturer’s instructions.
Cells were used for experiments (trypan blue exclusion test, western blot analysis and flow cytometry
analysis) described in the proper sections.
4.10. Patients
Altogether 58 therapy naive patients were consecutively enrolled who were diagnosed with
squamous cell carcinoma of the oropharynx, hypopharynx, and larynx at the Department of
Oto-Rhino-Laryngology and Head and Neck Surgery, Semmelweis University between 2012 and 2014.
All subjects gave their informed consent for inclusion before they participated in the study. The study
was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the
Semmelweis University’s Regional, Institutional Scientific and Research Ethics Committee (ethical
license No: 105/2014). The most important characteristics of our cohort are shown in Table 2.
Table 2. Patient characteristics at time of diagnosis.
Variable No. of Patients
Total no. of patients 58
Sex
Male 52
Female 6
Age (year)
Mean 58.45 (41–77)
Localization
Oropharynx 20
Larynx 20
Hypopharynx 17
Oral cavity 1
TNM 1 stage
I 6
II 9
III 13
IV A 23
IV B 4
IV C 3
1 TNM: tumor, node and metastasis, UICC TNM 7th edition.
4.11. Tissue Microarray (TMA) and Immunohistochemistry
TMA blocks containing 2 mm diameter cores of formalin-fixed, paraffin-embedded (FFPE) tissue
samples were created using the TMA Master tool (3DHISTECH Kft, Budapest, Hungary). Tissue
sections (4 µm) were cut on adhesion slides and were stained with hematoxylin and eosin, Bcl-2 and
Cx43. Antibodies used for immunohistochemistry are the same as those used for western blot.
BenchMark ULTRA IHC/ISH (Ventana Medical Systems, Oro Valley, AZ, USA) semi-automated
device was used for immunohistochemical staining with the application of U ultraView DAB v1.02.0018
kit. The protocol of staining method was carried out as described previously [4].
Briefly, sections were incubated at 72 ◦C for 4 min. We used EZ Prep Solution (Ventana) three
times to remove paraffin. Cell conditioning solution pH 9 (Ventana) was used for heat-induced epitope
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retrieval at 95 ◦C for 8 min followed by a heating at 97 ◦C for 76 min. Endogenous peroxidase activity
was inhibited with one drop UV INHIBITOR (Ventana), which was applied at 36 ◦C for 4 min. Primary
monoclonal antibody against Bcl-2 and Cx43 was applied at 36 ◦C for 120 min in a dilution of 1:100
respectively. After incubation with UV HRP UNIV MULT secondary antibody solution (Ventana)
at 36 ◦C for 8 min, peroxidase activity was visualized with diaminobenzidine (DAB) chromogen
(Ventana). Nuclear counterstaining was done with hematoxylin II (Ventana). All washing steps were
performed with diluted Reaction Buffer Concentrate (Ventana).
Bcl-2 categories were: 1: <10% positive tumor cells; 2: 11 to 30% positive tumor cells, 3: 31 to 60%
positive tumor cells; and 4: >60% positive tumor cells [40,41]. Cx43 staining was evaluated as follows:
1: <5% positive tumor cells; 2: 6 to 20% positive tumor cells, 3: 21 to 60% positive tumor cells; and
4: >60% positive tumor cells [14]. For statistical analysis, scores were dichotomized along different
threshold values. The most reproducible threshold for all assessors was set up when scores 1 and 2
were considered low protein expression, whereas scores 3 and 4 were taken high protein expression.
4.12. Statistical Analysis
Statistica 13 (TIBCO Software Inc., Palo Alto, CA, USA) software was used to carry out the
statistical analysis, measured values are indicated as mean ± standard deviation (SD). Student’s t-test
was used to compare groups. Two-sided test was selected. p < 0.05 value was considered as statistically
significant and all measurements were performed at least 3 times. When we examined the protein
and mRNA expression of HNSCC cell lines, Cx43 and Bcl-2 protein and mRNA expression of the
cells were compared to each other (Tables S2–S7). To determinate the IC50 value of paclitaxel on cell
viability of the studied cell line, we compared the IC50 points to each other (Tables S8 and S9). The
paclitaxel-induced apoptosis on HNSCC cell lines was examined in each case and in all concentration
by the comparison of the treated cell fractions to the control fractions (Tables S10–S13). When we
investigated the effects of GJA1 siRNA or Cx43 plasmid on the protein expression of HNSCC cell
lines, the expression pattern of all proteins in GJA1 siRNA treated samples were compared to protein
expression of the non-targeting siRNA treated cell samples, this method was applied in each cell line
(Tables S14 and S15). The expression pattern of all proteins in Cx43 plasmid treated samples were
compared to protein expression of the control plasmid treated cell samples, this method was applied in
each cell line (Tables S16 and S17). Analyzing cell viability in the GJA1 siRNA or Cx43 plasmid and
paclitaxel treated cell samples, the IC50 values of the cell lines were compared to each other (Tables
S18 and S25). When examining the effects of GJA1 siRNA on the paclitaxel-induced apoptosis of
HNSCC cell lines in non-targeting siRNA and GJA1 siRNA treated samples, the cell fractions -in each
concentration- were compared to the negative control fractions. The cell fractions of GJA1 siRNA
treated samples were also compared to the cell fractions of non-targeting siRNA treated samples
(Tables S19–S24).
For patient data, statistical analysis was performed using IBM SPSS Statistics for Mac version
20.0.0 (SPSS Inc., Chicago, IL, USA). The Pearson χ2 tests and the Fisher’s exact tests were used to test
correlations between discrete variables. In case of survival analysis, Kaplan-Meier estimation with
log-rank test as well as univariate and multivariate regression were applied. All tests were two-sided
and p-values <0.05 were considered statistically significant. Tumor localization, tumor size, stage,
lymph node metastasis, response to neoadjuvant chemotherapy and the biomarkers listed above were
used in the analysis (Table S26).
5. Conclusions
Based on these findings, we hypothesize that Cx43 expression has a control on Bcl-2 protein levels.
Elevated Cx43 and the concomitant low Bcl-2 levels result in an increased paclitaxel sensitivity. Since
taxanes are key components of induction chemotherapy for HNSCCs, testing for these biomarkers
in head and neck cancer patients might allow improved treatment planning and outcome prediction.
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Systemic retrospective analyses evaluating the possible correlation between therapeutic response and
the above molecular alterations can further validate our results.
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